key: cord-0839183-4qm3c682
authors: Riccio, Amanda A.; Sullivan, Eric D.; Copeland, William C.
title: Activation of the SARS-CoV-2 NSP14 3'-5' exoribonuclease by NSP10 and response to antiviral inhibitors
date: 2021-12-20
journal: J Biol Chem
DOI: 10.1016/j.jbc.2021.101518
sha: 9cf4e99830b33df0adc63866126372ca6bf11ad7
doc_id: 839183
cord_uid: 4qm3c682

Understanding the core replication complex of SARS-CoV-2 is essential to the development of novel coronavirus-specific antiviral therapeutics. Among the proteins required for faithful replication of the SARS-CoV-2 genome are NSP14, a bifunctional enzyme with an N-terminal 3'-to-5' exoribonuclease (ExoN) and a C-terminal N7-methyltransferase (N7-MTase), and its accessory protein, NSP10. The difficulty in producing pure, high quantities of the NSP10/14 complex has hampered the biochemical and structural study of these important proteins. We developed a straightforward protocol for the expression and purification of both NSP10 and NSP14 from E. coli and for the in vitro assembly and purification of a stoichiometric NSP10/14 complex with high yields. Using these methods, we observe NSP10 provides a 260-fold increase in k(cat)/K(m) in the exoribonucleolytic activity of NSP14 and enhances protein stability. We also probed the effect of two small molecules on NSP10/14 activity, remdesivir monophosphate and the methyltransferase inhibitor S-adenosyl homocysteine (SAH). Our analysis highlights two important factors for drug development: first, unlike other exonucleases, the monophosphate nucleoside analogue intermediate of remdesivir does not inhibit NSP14 activity; and second, SAH modestly activates NSP14 exonuclease activity. In total, our analysis provides insights for future structure-function studies of SARS-CoV-2 replication fidelity for the treatment of COVID-19.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of the current COVID-19 worldwide pandemic. SARS-CoV-2 is an RNA virus belonging to the Coronaviridae family. The Coronaviridae virus family was also responsible for the [2000] [2001] [2002] [2003] [2004] SARS outbreak and the Middle East Respiratory Syndrome (MERS), first detected in 2012 (1, 2) . At the time of this publication, SARS-CoV-2 infection has resulted in 4.3 million deaths worldwide and sweeping economic shutdowns, and continues to be transmitted at high rates (3) . Current therapeutics for the treatment of COVID-19 are limited. To date, the American Food and Drug Administration has approved only a single drug, Gilead Sciences Veklury (remdesivir), for the treatment of COVID-19 (4) . Remdesivir is a nucleoside analogue, based on a scaffold used to produce antiviral treatments for hepatitis B and C, as well as HIV, and was originally developed for the treatment of Ebola virus infections (5) (6) (7) . Since, remdesivir belongs to a broad-spectrum class of antiviral drugs that inhibit viral RNA synthesis, but more targeted therapeutics for the treatment of COVID-19 are needed.

The SARS-CoV-2 RNA genome encodes 29 proteins, of which 16 are non-structural proteins (NSPs) required to carry out the viral replication cycle (8) . In the treatment of coronaviruses, incorporation of nucleoside analogues, such as remdesivir, cause a delayed chain termination that results in aborted RNA synthesis. This activity is balanced with the excision of the analogues through 3'-5' proofreading exoribonucleolytic activity, promoting potential means of resistance (9, 10) . The key components of SARS-CoV-2 replication machinery are the RNA dependent RNA polymerase (RdRp) complex, which include the RNA polymerase, NSP12, and the processivity factors NSP7 and NSP8, as well as the proofreading nuclease, NSP14 and its coactivator, NSP10. Recent structural analysis highlights a network of the interdomain contacts between NSP14, NSP10 and NSP12 in the context of a capping and proofreading complex (11, J o u r n a l P r e -p r o o f 12) , yet the molecular mechanisms that define these interactions are still under investigation.

NSP14 is a bifunctional enzyme characterized by an N-terminal exoribonuclease domain named for the catalytic residues in the superfamily (DEDD) and a C-terminal methyltransferase (MTase) domain which catalyzes N7-guanosine methylation ( Figure 1A ) (13, 14) . NSP10 is a 139 amino acid protein that is an activator of both NSP14 and NSP16, a 2'-O-methyltransferase, which forms a crucial step in capping nascent mRNA (15) . In addition to sharing a coactivator, NSP14 and NSP16 are both S-adenosyl-L-methionine (SAM)-dependent MTases and generate S-adenosyl homocysteine (SAH) as a reaction byproduct.

At the writing of this publication, numerous publications have highlighted the difficulties encountered expressing full-length (FL) NSP14 in quantities required for structural studies in the absence of fusion peptides or coexpression with other NSP proteins. As noted by other studies, we were also unable to coexpress NSP10 and NSP14 in stoichiometric or near stoichiometric amounts (Supplemental Figure S1 ) (11, 16, 17) . Additionally, tethering two proteins on a single polypeptide can generate artificial or non-biologically relevant complex interactions or altered domain interfaces. Structural and enzymatic studies of NSP10/14 and other protein complexes can be significantly altered by large expression tags and nonstoichiometric coexpression of complexes, as demonstrated in (17). Overall, the lack of straightforward purification protocols of NSP10 and NSP14 have hampered biochemical and structural studies of this important SARS-CoV-2 complex. To this end, the mechanism and specificity of regulation in SARS-CoV-2 of NSP10 enhances exonuclease activity of NSP14, and the incorporation of metabolic reaction byproducts such as SAM/SAH or remdesivir monophosphate (RMP) are unknown.

Here, we present a straightforward bacterial expression and in vitro purification scheme to produce NSP14 and NSP10 individually in quantities useful for structural studies. While advantageous for future studies, individually purified NSP14 and NSP10 enabled the kinetic J o u r n a l P r e -p r o o f characterization to define the enzymatic advantage of NSP10 on NSP14 exoribonuclease activity. We observed NSP10 increases both the catalytic efficiency of NSP14 exoribonucleolytic activity by up to 260-fold, and enhances the overall protein thermal stability. Furthermore, we determined that, unlike other exonucleases, NSP14 exonuclease activity is not inhibited by the monophosphate intermediate of remdesivir. These purification methods and biochemical analyses begin to lay the groundwork for future structural studies defining the mechanism of SARS-CoV-2 viral synthesis as well as designs for future therapeutic treatments.

The difficulty around the expression and purification of NSP14 FL has led to a lack of thorough biochemical analyses. Here, we report a new method for the expression and purification of both NSP10 and NSP14, individually, in quantities sufficient for structural studies in the absence of fusions, coexpressions, or variable tags. This approach has allowed us to probe the effect of NSP10 on NSP14 FL. Briefly, we grew bacterial Rosetta2™ pLacI (DE3) competent cells with plasmids for either pDest527 (N-terminal his-tag) NSP10 or NSP14 FL in terrific broth (pH 7.2) media, 3L and 6L, respectively. Cultures were inoculated and grown at 37 ˚C to an OD600 = 2, accomplished in approximately 4 hours and induced with the addition of 0.2 mM IPTG. NSP10 bacterial cultures were grown for another 4 hours at 37 ˚C and harvested 4K rpm for 25 mins. In comparison, overnight expression of NSP10 led to a substantial decrease in final protein yield (data not shown). NSP14 cultures were grown overnight at 16 ˚C.

Purification of NSP10 and NSP14, individually, was carried out via a relatively straightforward two (NSP10) or three (NSP14)-column purification scheme: (cytiva columns) (i) 5mL Ni-NTA hp, (ii) 5 mL heparin HP (NSP14 only), (iii) S200 increase. To achieve the most highly purified Figure S2) . Also, noteworthy, individually, NSP14 and NSP10 and the complex were concentrated in excess of 10 mg L -1 without visible effects to solubility.

After purifying the individual proteins, as described above ( Figure 1B ), NSP10 and NSP14 were combined, with NSP10 in 10-fold molar excess ( Figure 1C ). This protein mixture was then diluted to 50 mM NaCl final using dilution buffer and loaded on a Cytiva Mono S™ 5/50 GL column. NSP14 and NSP10 can be concentrated before loading onto the Mono S at 50 mM NaCl without compromising solubility or final protein concentration. The mono S column was run at 10 mL/min, washed with buffer A (5CV) and eluted with a linear gradient over 15 CV from 50 mM NaCl to 1 M NaCl. The NSP10 isoelectric point (PI 7.95) is such that it does not bind tightly to the Mono S resin in the buffering conditions used. Therefore, the majority of the 10-fold excess NSP10 will either flow through the column during loading or will elute very early in the column wash or linear gradient wash ( Figure 1C , peak 1). The second peak of the elution represents the formed complex, consisting of near stoichiometric amounts of NSP14 and NSP10 ( Figure 1C , peak 2). The complex charge is sufficiently different from either individual protein such that the complex elutes before free NSP14 ( Figure 1B , peak 1 and peak 3). Given that NSP10 was in 10-fold excess, very little unbound NSP14 eluted. The stoichiometric, pure complex achieved by this technique is unlike that formed by prior methods for the SARS-CoV-2 NSP10/14 complex (11, 18, 19) . Final yields of the complex from the Mono S column are approximately 0.6 mg L -1 of culture. We believe this method of expression and purification will further enhance the capabilities to perform ongoing studies of replication/transcription complex and molecular mechanisms underlying capping the nascent SARS-CoV-2 mRNAs.

With our purified NSP10 and NSP14 and the stoichiometric complex, we were uniquely positioned to perform biochemical characterization of both components individually, as well as J o u r n a l P r e -p r o o f assembled and purified as an NSP10/14 complex. In SARS-CoV-1, it was shown that NSP10 enhances the exonuclease activity of NSP14 (20, 21) . However, it was unknown to what degree NSP10 enhanced the exonuclease activity of the SARS-CoV-2 NSP14 FL. To address this question, the 3' exonucleolytic activity of NSP14 was measured alone and within the NSP10/14 complex. Exonuclease activity was measured on a 5' Cy5-labeled 20-mer RNA primer annealed to an unlabeled 28-mer RNA complement. An 8-nucleotide single-stranded overhang exists at activity was also measured at 500 nM and 2.5 µM protein concentrations. Further, the activity of NSP14 alone was measured at time points longer than was required for NSP10/14 complex ( Figure 2B , insert). Due to a slower rate of cleavage product formation, a 60-minute time course was used to yield comparable amounts of product. Initial rates (Vo) were determined from these reaction progress curves and plotted in Figure 2C with respect to substrate concentration. Initial rates for the NSP10/14 complex and NSP14 alone are plotted on the Y-axis (left and right, respectively). In Figure 2C , the plot demonstrates that initial rates are linearly dependent on Figure S3) . While preparing this publication, an X-ray crystallography structure of NSP10 and NSP14 N-terminus DEDD domain (residues 6-294) was published (PDB ID: 7DIY) (19) . The solvent-exposed surface of NSP14, specifically the region in close proximity to the NSP10 binding site, is composed primarily of positively charged residues ( Figure 2E , left). When NSP10 and NSP14 form a molecular complex, as displayed in the crystal structure ( Figure 2E , right), the solvent exposed positively charged area increases. The change in electrostatic potential of the complex likely accounts for an earlier elution of the complex from a Mono S column under a linear NaCl gradient. Taken together, the enhanced positive solvent exposed interface and the increased thermal stability imparted by NSP10 within In addition to the N-terminal exonuclease activity of NSP14, the C-terminal domain possesses methyltransferase activity important for RNA capping (11) . It is well documented that the methyltransferase reaction product S-adenosyl-homocysteine (SAH) is a non-specific inhibitor of methyltransferases (26) . Consistent with this, it has been shown that SAH inhibits the methyltransferase activity of NSP14 (27) , yet it is unclear the impact SAH may have on the nuclease activity of NSP14. To address this issue, we first used DSF to determine the impact that SAH imparts on the thermal stability of NSP14 and NSP10/14 complex. We titrated SAH at 0 µM, 40 µM, 400 µM and 4 mM ( Figure 4A ). Interestingly, we observed a very substantial increase in NSP14 protein stability in the presence of SAH. In control conditions, the Tm of Figure 4B ). We also measured the exonuclease activity at increasing concentrations of SAH ( Figure 4C ). SAH leads to an increase in kcat/Km, suggesting that SAH imparts a modest activation of NSP10/14 exonuclease activity, with a K1/2,act = 25 +/-9 µM. This activation constant is consistent with the observed increasing Tm upon SAH binding from 0 -40 µM and plateauing in the mid to high micromolar range.

Overall, the COVID-19 pandemic, the rapid spread of the SARS-CoV-2, and the deadly consequences of contracting SARS-CoV-2 have highlighted the need for additional and more specific viral inhibitors targeting coronaviruses. The primary target for nucleoside analogue viral inhibitors is thought to be NSP12 and, to a lesser extent, NSP14 (28) . It is also speculated that regulation of coronavirus genome fidelity may rely exclusively on NSP10/12/14 (29) . Targeting NSP14 and NSP14 in complex with its coactivator NSP10, therefore, could prove to be a viable target in the treatment of COVID-19. Here, we have established a straightforward purification scheme, and, importantly, we have introduced a copurification strategy that can be used to generate an active stoichiometric protein complex for the SARS-CoV-2 exoribonuclease. Unlike the observed reconstituted exonuclease activity of SARS-CoV-1 NSP10/14(30), we were not able to reconstitute NSP14 exonuclease activity by titrating NSP10. While we cannot rule out expression systems or protein affinity tag, others have noted that these proteins expressed and purified form E. coli were not active or able to stimulate (17) as compared to eukaryotic expression systems. We believe this highlights the utility of the stoichiometrically purified complex for SARS-Cov-2. To this end, in vitro purification has the potential to promote additional biochemical and structural analyses of the NSP10/14 complex and ultimately lead to a structureguided approach aiding in the design of inhibitors.

A recent publication has shown a quaternary complex of NSP10, NSP14, NSP8 and RNA (18) .

In this complex, RNA is bound in the positive electrostatic patch that is formed upon NSP14/NSP10 complex formation ( Figure 2E, right) . The positioning of nucleic acid is consistent with our analyses of NSP10 coactivator stabilizing the protein structure of NSP14 FL and increasing the N-terminal exonucleolytic activity. It is likely that the enhanced electrostatic potential provides a better compliment for the negatively charged RNA, however, to date, a thorough thermodynamics study of SARS-CoV-2 NSP14/NSP10 RNA binding has not been biochemically investigated. With the most recent structures and a mechanism for copurification it would be interesting to generate mutations in the RNA binding surface and the NSP10/14 interface to determine the molecular components that define this ternary complex. Given the increased Tm, changes to the electronegative patch, and the increased second order rate constant, it's tempting to speculate that the interface of NSP10/14 allows for enhanced RNA binding. We cannot eliminate the possibility that the NSP10 interface promotes an allosteric NSP16 promotes the cap-1 structure adding a methyl group onto the cap-0 structure and is completely inactive in the absence of NSP10 in SARS-CoV-1 (30) . It is proposed that NSP10 allosterically activates NSP16 and helps to assemble the MTase active site (32) . Here, we observe that while NSP14 is capable of exoribonuclease activity, the activity is orders of magnitude lower than the activity of the NSP10/14 complex. Additionally, NSP14 has a lower Tm in the absence of NSP10. The inherent instability may partially explain difficulties in obtaining an NSP14 Apo structure and the difficulties of in vitro purification for NSP14 observed in previous publications. Despite this, the binding interface of NSP10/14 and NSP10/16 J o u r n a l P r e -p r o o f significantly overlap and future studies will be needed to determine the dynamic balance of NSP10 as an activator of both NSP14 and NSP16.

As the only FDA-approved antiviral therapeutic for COVID-19, it is critically important to understand the impact of remdesivir on multiple components of the SARS-CoV-2 core replication complex. While it is known that incorporation of remdesivir into a growing RNA by NSP12 causes delayed chain termination (15) it is unknown whether NSP14 is a secondary target of remdesivir. Remdesivir is supplied as a pro-drug and must be metabolized in vivo to the active triphosphate drug. During this process, RMP is formed ( Figure 3A ). Previous studies have demonstrated that chain-terminating antivirals may accumulate as nucleotide analogue monophosphates, and that these compounds can directly inhibit the exonucleolytic proofreading function of host polymerases (25) . In SARS-CoV-2, NSP14 functions as the replication proofreading exonuclease. We have shown here that RMP, even at low millimolar concentrations, does not inhibit NSP14 exonuclease activity. Given the current remdesivir dosage guidance (33), it does not appear that accumulated RMP inhibits NSP14 as a secondary target during treatment and may leave open the possibility of a dual-drug approach that also impedes NSP14 proofreading activity.

NSP14 is a dual function enzyme, with these separate functions being housed at either the N-(exonuclease) or C-(MTase) terminal domain. However, these two domains share an extensive interface (19) . It has been shown that NSP14 C-terminal MTase activity does not require NSP10 and is, in fact, robust in the absence of NSP10 consistent with our observation that NSP14 is stabilized by SAH above the IC50 for inhibition of the C-terminal activity (16, 27) . The C-terminal MTase activity of NSP14 has been targeted for small molecule inhibitor design (17, 27) .

Surprisingly, we observed a small but significant increase in the exonucleolytic kcat/Km. Given Data Availability -All data are contained within the article and in the supporting information.

Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia

SARS-CoV-2, SARS-CoV, and MERS-CoV: A comparative overview

An interactive web-based dashboard to track COVID-19 in real time

FDA Approval of Remdesivir -A Step in the Right Direction

The journey of remdesivir: From Ebola to COVID-19

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach

Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease

Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites

Coupling of N7-methyltransferase and 3′-5′ exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading

Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA

A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping

Coronavirus genomic nsp14-ExoN, structure, role, mechanism, and potential application as a drug target

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

New targets for drug design: importance of nsp14/nsp10 complex formation for the 3'-5' exoribonucleolytic activity on SARS-CoV-2

Structural basis of mismatch recognition by a SARS-CoV-2 proofreading enzyme

Crystal structure of SARS-CoV-2 nsp10 bound to nsp14-ExoN domain reveals an exoribonuclease with both structural and functional integrity

RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex

Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex

Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19

Effects of 3′-azido-3′-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cells

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

Differential Incorporation and Removal of Antiviral Deoxynucleotides by Human DNA Polymerase γ

SAM/SAH Analogs as Versatile Tools for SAM-Dependent Methyltransferases

Probing the SAM Binding Site of SARS-CoV-2 Nsp14 In Vitro Using SAM Competitive Inhibitors Guides Developing Selective Bisubstrate Inhibitors

2020) A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19

Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential Therapeutics

In vitro reconstitution of sars-coronavirus mRNA cap methylation

Binding of the Methyl Donor S-Adenosyl-l-Methionine to Middle East Respiratory Syndrome Coronavirus 2′-O-Methyltransferase nsp16 Promotes Recruitment of the Allosteric Activator nsp10

SARS-CoV-2 Nsp16 activation mechanism and a cryptic pocket with pan-coronavirus antiviral potential

Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit

A flexible genome-scale resource of SARS-CoV-2 coding sequence clones

We thank Drs. Bradley Klemm and Joseph Dahl for their critical reading of this manuscript and insightful discussions. We thank the NIEHS Structural Biology Core facility, specifically Tom Stanley of the Protein Expression Facility for performing the LR reactions of NSP10 and NSP14 into pDEST527.

This work was supported by Projects Z01 ES065078 and Z01 ES065080 to W.C.C from the Division of Intramural Research of the NIH, NIEHS.

AAR EDS WCC conceptualized study and wrote, reviewed, edited document. AAR and EDS performed all data analysis, investigation, visualization, and methodology WCC provided funding acquisition and supervision.

The authors declare that they have no conflicts of interest with the contents of this article. J o u r n a l P r e -p r o o f